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INTRODUCTION
The regulation of programmed cell death (also known as apoptosis) is a process critical for both normal embryonic development and turnover of healthy tissue in the adult. In a number of disease states, however, the pivotal balance between pro-apoptotic and cell survival signals is disrupted, leading to loss of healthy cells as in neurodegenerative disorders or failure to eliminate genetically damaged cells leading to cancer (Evan and Vousden, 2001; Green and Evan, 2002 ).
The mechanisms controlling cellular self-destruction programs are tightly controlled and many physiological growth control signals that govern cell proliferation and tissue homeostasis are linked to apoptosis (Evan and Vousden, 2001; Gozani et al., 2002; Green and Evan, 2002) .
Apoptosis pathways can be activated in a cell specific manner by a diversity of distinct triggers including death receptor ligands such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas and TNF-α, retinoids, genotoxins, oxidative stress, nutrient deprivation and anoikis (anchorage dependence-mediated cell death).
The vitamin A metabolite, all-trans-retinoic acid (RA) is an essential signaling molecule in embryonic development and throughout life; a potent regulator of cell differentiation, proliferation and apoptosis in various cell types (Durston et al., 1989; Means and Gudas, 1995) .
RA acts through specific RA nuclear receptors (RARα, β & γ) and their heterodimeric counterparts, the retinoid-X-receptors (RXRα, β & γ) to positively or negatively regulate expression of RA target genes by binding to their respective response elements (RAREs) (Kastner et al., 1995; Mangelsdorf and Evans, 1995) . Disruptions in retinoid signaling through mutations in nuclear receptors RARs and RXRs have been found in certain types of tumor cells MOL#5769 (de Thé, 1996) . Vitamin A deficiency has been linked to increased susceptibility to carcinogenesis in animal models and appears to be causally associated with tumor formation and progression (First reported by Wolbach and Howe, 1925;  for review see Lotan, 1996) .
While essentially all cell types express nuclear retinoic acid receptors, cellular responsiveness is determined by RA bioavailability regulated by the coordinated balance between vitamin A nutritional status and RA biosynthesis, and catabolism. We and others have previously demonstrated that expression of the RA metabolizing cytochrome P450s, CYP26A1, B1 and C1, protect cells and tissues from exposure to RA (generated by retinaldehyde dehydrogenase enzymes) during embryogenesis by restricting RA access to transcriptional machinery by converting RA to rapidly excreted oxo-derivatives (4-OH RA, 4-oxo RA, 18-OH RA) (White et al., 1997; MacLean et al., 2001; Abu-Abed et al., 2001; Tahayato et al., 2003; Taimi et al., 2004) . CYP26 enzymes may play a similar but separate role in limiting the consequences of fluctuations in nutritional vitamin A. The possibility that pathological conditions such as cancer might involve aberrant expression of CYP26A1 has recently emerged from several studies. Elevated CYP26A1 expression and RA catabolic activity have been detected in breast epithelial adenocarcinoma cells in culture (Van heusden et al., 1998) , leukemic cells from patients with acute promyelocytic leukemia (APL) (Ozpolat et al., 2002) and cells derived from squamous cell carcinoma from head and neck cancers (Klaassen et al., 2001) , however, the relevance of elevated CYP26A1 activity in tumor cells remains to be fully clarified.
In the present study, by overexpressing CYP26A1 in various cell lines, we wanted to generate a state of RA deficiency in cultured cells to examine whether RA was an obligatory component of MOL#5769
MATERIALS AND METHODS
Cell line and culture. All cell lines were maintained in DMEM (Gibco BRL, Burlington, ON) supplemented with 10% FBS, 10 mM HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere unless otherwise specified.
Construction of expression vector and transfection.
Full length human CYP26A1 cDNA was amplified by reverse transcriptase (RT) -polymerase chain reaction (PCR) from 1 µg total RNA extracted from RA-treated MCF-7 cells, which was reported to be CYP26A1-inducible after 1 µ M RA treatment (White et al., 1997) , using an EcoRI site-tagged forward primer (5'-GAATCCATGGGGCTCCCGGCGCTGCT-3') and a BamH1 site-tagged reverse primer (5'-GGATTCTCAGATTTCCCCATGGAAAT-3'). After subcloning into a TA-cloning vector (pCR ® II) using a TA cloning kit (Invitrogen, Burlington, ON), the digested 1505 bp EcoRIBamHI fragment was ligated into the response plasmid, pEGFP (enhanced green fluorescent protein)-C1 (Clontech, Palo Alto, CA) designated as pEGFP-C1-CYP26A1 plasmid. The integrity of the final pEGFP-C1-CYP26A1 construct was confirmed by sequence analysis. As a control vector, pCMS-EGFP-CYP26A1 plasmid, which has separate transcription cassettes containing EGFP and CYP26A1 cDNA, was made by the same method except in using an EcoRI site-tagged forward primer (5'-GAATCCGCCGCCACCATGGGGCTCCCGGCGCTGCT-3') and a XbaI-tagged reverse primer (5'-TCTAGATCAGATTTCCCCATGGAAAT-3') for PCR and pCMS-EGFP as an expression vector (Clontech).
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pEGFP-C1-CYP26A1 alone (5 µg), or plasmid mixture of pCMS-EGFP-CYP26A1 (5 µg) plus pcDNA3.1(-) (1 µg) were transfected into a number of different cell lines containing HeLa, human cervical cancer cells; MCF-7, human breast cancer cells; A549, non-small cell lung cancer cells; and Hep3B, human hepatocellular carcinoma cells, using Lipofectoamine TM reagent (Gibco BRL). G418 (800 µg/ml, Sigma-Aldrich, Oakville, ON)-resistant clones were screened by immunofluorescence microscopy followed by culturing on glass coverslips (Fisher Scientific, Toronto, ON) to confirm expression of EGFP or EGFP fusion proteins. Stably transfected clones were also screened both by Northern blot analysis for CYP26A1 mRNA expression and metabolic assay for measuring the metabolism of radiolabelled RA ( 3 H-RA) as described previously (White et al., 1997) .
Cell death analyses. Cells were plated at 1 x 10 5 cells per 6 well plates and incubated for 24 h prior to 5 min pulse-treatment of 0.1 µM RA or various concentrations as indicated, and were washed twice with phosphate buffered saline (PBS) followed by replacement with DMEM supplemented with 10% charcoal-dextran treated FBS. To avoid the significant accumulation of RA metabolites, RA treatment was very short (5 min), which is known to be sufficient to switch on the RARE-driven transcriptional machinery. Subsequently, apoptosis was stimulated with TRAIL (R&D Systems, Minneapolis, MN) at a dose range of 0 to 20 ng/ml for 0.5 h up to 24 h.
These cells were also treated with various death-inducing agents including agonistic Fas antibody (0.025 to 10 µg/ml, clone CH-11, Panvera, Madison, WI), TNF-α (1 to 100 ng/ml, R&D Systems), H 2 O 2 (50 or 100 µM), cisplatin (CDDP, 10 µg/ml), etoposide (VP16, 50 µM), heat shock at 42°C for 30 min and γ-irradiation (20 Gy). In some experiments, ketoconazole (0.5 MOL#5769 µM to 10 µM, Sigma-Aldrich) was added 4 h before apoptotic stimulation and then maintained throughout the experiments.
Apoptotic assays and quantification were previously described in detail (Osanai et al., 1997) . Briefly, floating dead cells were pelleted by centrifugation and washed with PBS. The pellet was resuspended in lysis buffer containing 10 mM Tris-HCl (pH 8.0), 10 mM EDTA and 0.5% Triton X-100, and centrifuged at 12,000 xg for 10 min at 4°C. Each supernatant, which preferentially contains low molecular weight cellular DNA, was once extracted with phenol/chloroform (1:1) and the fragmented DNA was ethanol-precipitated. Gel electrophoresis of the DNA samples was performed on 2.5% agarose gels and ladder formation due to fragmentation was visualized with ethidium bromide under ultraviolet illumination.
The DNA fragmentation rate was also quantified by the method as described (Osanai et al., 1997) . Briefly, total cells in the tissue culture wells were harvested, washed with PBS and lysed with lysis buffer containing 5 mM Tris-HCl (pH 8.0), 20 mM EDTA, and 0.5% Triton X-100 for 15 min at 4°C. The cells were then centrifuged at 12,000 xg for 20 min at 4°C to separate intact chromatin in the pellet from DNA fragments in the supernatant. The DNA amounts in each pellet and supernatant were determined using a diphenylamine reagent and the fragmentation rate (%) was expressed as (fragmented DNA / total DNA) x 100.
DAPI staining. Cells grown on glass coverslips for confocal microscopy were washed once with PBS and then incubated in DAPI ((4',6-diamidino-2-phenylindole)-methanol) (1 µg/ml; Molecular Probes, Eugene, OR) solution for 15 min at 37°C.
Cell counting, Giemsa staining and mitotic index measurement. These assays were performed as described in detail elsewhere (Hsu et al., 1999) . The mitotic index was estimated by counting at least 1000 cells of each treatment at x 400 magnification by light microscopy.
The percentage of mitotic cells was calculated.
Cell cycle analysis by flow cytometry. Cells on 100 mm tissue culture dishes were treated with 0.5 µM RA for 5 min prior to harvesting by centrifugation, and permeabilized with ice-cold 70% ethanol for at least 30 min. After washing with PBS, cells were treated with PBS containing 100 µg/ml DNase free-RNase A at 37°C for 30 min. After centrifugation, cells were suspended in PBS containing 50 µ g/ml propidium iodide (PI) and stained at 37°C for 30 min. DNA content was analyzed by FACScan (Becton Dickinson).
Western blot analysis. EGFP and EGFP fusion protein, Bcl-X L , caspase-3, cytochrome c, p21 Waf1 and β -actin protein levels were examined by Western blot analysis. Cell fractionation and mitochondrial isolation were performed as previously reported (Yang et al., 1997 we used a fusion construct comprising the entire coding region of the CYP26A1 cDNA linked to the EGFP encoding gene (pEGFP-C1-CYP26A1). We first determined the differential sensitivity of these cells to a 24 h exposure to TRAIL, which activates cell-death response through the death receptor mediated pathway. Prior to treatment with TRAIL, cells were briefly exposed to a pulse of 0.1 µM RA. RA increased the sensitivity of HeLa cells to TRAIL-induced apoptosis in wt cells, however, HeLa CYP26A1 cells showed significant resistance to synergistic apoptotic effects of TRAIL in the range of 0.025 ng/ml to 20 ng/ml with 0.1 µM RA ( To evaluate how general the suppressive effect of CYP26A1 expression was on TRAIL signaling, we stably transfected other cell lines including MCF-7, A549 and Hep3B cells, with the same construct to establish overexpressing clones. Although these cell types were responsive to TRAIL-mediated apoptosis, CYP26A1 expression had similar suppressive effects on cell responsiveness with or without pretreatment of RA ( Fig. 1F and data not shown).
We also overexpressed another cytochrome P450, CYP24 involved in the metabolism of 1α, 25-dihydroxyvitamin D3, in both HeLa and A549 cells, however, we were unable to detect any effect of CYP24 on the apoptotic potential of these cells (data not shown), suggesting that the antiapoptotic effect is CYP26 specific.
Apoptotic suppression by CYP26A1 is not specific for TRAIL-mediated apoptosis. We next determined whether the suppressive role played by CYP26A1 was applicable to other apoptogenic stimuli including oxidative stress, heat shock, genotoxic agents and γ-irradiation.
CYP26A1 expression resulted in the appreciable inhibition of apoptotic cell death against these stimuli ( Fig. 2A and B), suggesting that the protective role of CYP26A1 against apoptosis could be observed following exposure to a broad range of cell stressors.
Direct interactions between RA metabolism and the susceptibility of apoptotic cell death.
Ketoconazole, a broad-spectrum inhibitor of cytochrome P450s which we have previously shown can inhibit CYP26A1 activity (Chithalen et al., 2002) , was next employed to establish whether the effect of CYP26A1 on cell death inhibition was mediated by its role in conversion of RA into polar metabolites. Expression data of HeLa CYP26A1 cells is shown, in which CYP26A1-EGFP This article has not been copyedited and formatted. The final version may differ from this version. fusion protein could be clearly detected by Western blot analysis using EGFP antibody, revealing strong catabolic activity of RA that was inhibited by ketoconazole treatment ( Fig. 3A and B).
Ketoconazole alone did not significantly affect cell viability. While other members of the TNF family such as Fas and TNF-α could induce apoptosis in wt cells, the cells overexpressing CYP26A1 were also protected from these apoptogenic factors (Fig. 3C ). Pretreatment of CYP26A1 transfected cells with ketoconazole, however, restored sensitivity of these cells to cell death stimuli, suggesting that the catalytic activity of this enzyme was important for its antiapoptotic effect on these cells.
The RARα-selective compounds Am80 (4[(5, 6, 7, 5, 8, carbamoyl]benzoic acid) and Am580 (4(5, 6, 7, 5, 8, naphtamido)benzoic acid), which are resistant to metabolism by CYP26A1, were reported to stimulate apoptosis in susceptible cells as efficiently as RAR-panactive retinoids including RA (Schneider et al., 2000; Luu et al., 2001) . We used these reagents to further demonstrate the direct relationship between CYP26A1-mediated RA catabolism and apoptosis resistance. In a dose range from 0.5 to 10 nM, a clear dose dependence of apoptosis was found in cells that were treated with Am80 and Am580 (data not shown). The treatment of cells with these reagents in combination with death receptor ligand abrogated the inhibitory effect of CYP26A1 expression on TRAIL-, Fas-or TNF-α-mediated apoptosis in HeLa CYP26A1 cells (Fig. 3D ). Am80 was not as effective as Am580 in inducing apoptosis in HeLa cells, requiring approximately 5-fold higher concentrations to produce similar effects. These data strongly indicate that RA metabolism is associated with the suppression of apoptotic responsiveness in CYP26A1 expressing cells.
This article has not been copyedited and formatted. The final version may differ from this version. 3E and data not shown), which is consistent with previous literature (Daly et al., 1989; Geisen et al., 1997) . Together with our observation that the cells respond comparably to RA under all conditions even when CYP26A1 is overexpressed as well as Am80/Am580, this result indicates that the gain-of-function effects of CYP26A1 on apoptosis could be mediated through a RAR mechanism of action.
The apoptosis sensitizing effect of RA has been demonstrated in a number of different experiments. Although the effect may be less than that observed for Am80 and Am580, it is consistent and significant. We have observed the RA effect on pro-apoptogenic agents in many different cell lines and observed different levels of response. The difference between the RAresponse observed in Fig. 3C (comparing top and bottom panels) reflects differences in cell type.
Why some cell lines respond better than others may reflect inherent differences in the induction of endogenous CYP26A1, B1 and/or C1. HeLa cells, for example, are known to express CYP26A1 and B1, and both enzymes are inducible by RA (our unpublished result).
CYP26A1 overexpression mediates aberrant mitotic progression. Many lines of evidence
indicate that apoptosis is linked to cell cycle events (Evan and Vousden, 2001 ). To determine the potential association of CYP26A1 expression with cell cycling, we investigated the differences of cell growth rates, cell cycle analysis and mitotic index between CYP26A1
expressing and non-expressing cells (Fig. 4) . CYP26A1 expression had a slight promoting effect This article has not been copyedited and formatted. The final version may differ from this version. on cell proliferation (Fig. 4A ), but had a much greater effect on mitotic index (Fig. 4B ). The effect of RA was minimal on cell growth; however, mitotic index was significantly suppressed by RA treatment in wt cells. By contrast, a decrease in mitotic index induced by RA was significantly abrogated in HeLa CYP26A1 cells even when both TRAIL and RA were added to the cultures (Fig. 4B) . Cell cycle analyses clearly indicated that RA-induced G1 arrest and a concomitant decrease in S-phase fractions were partially abrogated in HeLa CYP26A1 cells, suggesting that CYP26A1-induced RA catabolism involves the G1/S phase transition and allows cells to escape from RA-mediated specific cell cycle checkpoints (Fig. 4C ).
Altered gene-expression profile provides anti-apoptotic state in CYP26A1 expressing cells.
In order to explore the molecular mechanisms of the apoptotic suppression due to CYP26A1 expression, we screened the gene-expression profile with the GEArray system. Total RNA was isolated from wt and HeLa CYP26A1 cells that had been cultured for 24 h with or without 1 µM RA and aliquots of 5 µg total RNA was reverse-transcribed into cDNA, labeled with 32 P and hybridized to GEArray apoptosis pathway-specific gene array membranes. Some differences of gene-expression profile between wt and HeLa CYP26A1 cells were observed without RA stimulation, however, the differences were more apparent in the presence of RA (Fig. 5A ).
Although CYP26A1 overexpression induces upregulation of apoptosis-inhibitory genes such as bcl-x, bcl-w and bcl-2 and conversely downregulation of apoptosis-inducing genes such as bad, bax and bak, we observed more marked changes in inhibitor of apoptosis protein (IAP) family genes including survin, IAP-1 and -2, and XIAP. CYP26A1 expression also upregulates a number of TNF ligand family members, however, its expression concomitantly decreases a This article has not been copyedited and formatted. The final version may differ from this version. Cytochrome c is normally located in the intermembrane space of mitochondria and its release is known to be one of the upstream mitochondrial events that can contribute to caspase activation (Ferri and Kroemer, 2001) . Once the cytochrome c is released into the cytosol in response to apoptotic stimulation, it initiates a caspase activation cascade (Ferri and Kroemer, 2001 ). We next examined whether CYP26A1 expression affects cytochrome c release (Fig. 5B) .
We found that cytochrome c was largely located in the mitochondria in both wt and HeLa (Fig. 4) .
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DISCUSSION
Apoptosis is an evolutionarily conserved process in normal embryogenesis, tissue homeostasis and regulation of the immune system (Fisher, 1994; White, 1996) . Many studies have implicated RA as an important regulator of this process and certain types of tumor cells apoptose following RA treatment (Fisher, 1994; White, 1996) . RA has been shown to enhance sensitivity of certain cells to a number of pro-apoptogenic factors, including death receptor ligands such as TRAIL. Our present studies show that the expression of the RA metabolizing enzyme CYP26A1 significantly abrogates the proapoptotic activity of RA and its synergistic activity with apoptosis-inducing factors, resulting in the suppression of cellular response to several differently acting triggers of apoptosis. We also observed a reversal of the cytostatic effects of RA in CYP26A1 overexpressing cells as measured by changes in cell growth and mitotic index. Cultured cells overexpressing CYP26A1 gain significant resistance to apoptosis signaling possibly due to a state of reduced RA bioavailability caused by metabolic inactivation of RA. However, we cannot exclude the possibility that forced expression of CYP26A1 may have some additional interesting but as yet uncharacterized effects on the cells.
One possible alternative explanation for effect of CYP26A1 overexpression on apoptosis is that RA metabolites generated by CYP26A1 may have anti-apoptotic activities. However, this is unlikely since ketoconazole can partially restore the RA enhanced sensitivity to proapoptotic agents suggesting that RA but not its metabolites are likely responsible for this enhancement effect. In addition, synthetic retinoids (such as Am80 and Am580) that are not metabolized by CYP26A1 can also enhance sensitivity to proapoptotic agents, these findings support one This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3C) . We cannot presently explain this observation, however, one possibility is that the period of time required for clonal expansion in RA-free conditions (due to Loss of responsiveness to inducers of cell death is a contributing factor in the progression of a cell toward a malignant phenotype, because it is now believed that impaired or decreased susceptibility to respond to various apoptotic signals has been associated with oncogenic transformation rather than enhanced cell growth (Evan and Vousden, 2001; Green and Evan, 2002; Gozani et al., 2002 This is consistent with observations in experimental animals indicating a link between vitamin A deficiency and increased tumor formation. This may also provide a plausible explanation for the increased incidence and higher risk of development of cancer observed in vitamin A deficient individuals (Wolbach and Howe, 1925; Lotan, 1996) . In addition, enhanced RA metabolism has been observed in several types of cancer including head and neck squamous cell carcinomas along with elevated levels of CYP26 enzymes in a number of cancer cell types (Van heusden et al., 1998; Klaassen et al., 2001; Ozpolat et al., 2002) . Whether RA metabolism contributes to tumor formation and/or progression remains to be determined.
Because of the strong antiproliferative and differentiation-, and apoptosis-inducing effects on cancer cells both in vitro and in vivo, retinoids show promise in the treatment and chemoprevention of epithelial carcinogenesis and in cancer differentiation therapy (Lotan, 1996; Hong and Sporn, 1997; Hansen et al., 2000) . In this regard, the most striking chemical use of retinoids is for differentiation therapy of APL based on the ability of retinoids to induce differentiation of leukemic promyelocytes and a growing body of evidence indicates that a high proportion of patients with APL achieve complete remission after short-term treatment with RA (Huang et al., 1988; Muindi et al., 1992; Fenaux and Degos, 1997) . However, this high rate of remission is brief and relapse occurs in most cases; patients gain progressive clinically acquired resistance to further treatment with RA (Fenauz and Chomienne, 1996) . Several lines of This article has not been copyedited and formatted. The final version may differ from this version. evidence suggest that clinically acquired resistance to RA treatment may be partially due to increased RA metabolism and we have also previously shown that NB4 cells derived from APL patients exhibit inducible expression of CYP26A1 after RA pretreatment (White et al., 1997) .
Increased RA catabolism may not only reduce cell sensitivity to RA but also as a consequence reduce effectiveness of proapoptotic agents whether endogenous or therapeutic; thus blocking RA catabolism in conjunction with treatment with proapoptotic agents may be an effective therapeutic strategy to treat malignancies where CYP26 enzymes are expressed. Imidazole derivatives (ketoconazole, liarozole) have been shown to potentiate the apoptotic effects of cell death-inducing agents in a variety of cancers and showed clinical effectiveness in treatment of cancer patients, although the underlying mechanisms of how these agents could induce proapoptotic effects are not fully understood (Mahler et al., 1993; Wang et al., 2002) . Whether at least part of the effectiveness of combining P450 inhibitors with apoptogenic agents is due to blocking RA catabolism remains to be determined. Since we have shown that synthetic retinoids resistant to metabolism can restore sensitivity of CYP26A1 expressing cells to apoptogenic agents, such retinoids might also be useful for therapeutic strategies involving combination therapy. These studies also demonstrate for the first time that retinoids can synergize with γ-irradiation, suggesting that retinoids and/or RA metabolism inhibitors may also be used to enhance the efficiency of radiation therapy.
Gene-expression profiles have demonstrated that a large number of signaling pathways are associated with the suppression of apoptotic cell death due to CYP26A1-mediated RA depletion. Previous studies have shown that two major pathways exist in transmitting the death signals to the apoptosis-executing compartment (Scaffidi et al., 1998) . In "type I" cells, This article has not been copyedited and formatted. The final version may differ from this version. triggering an initiator caspase (e.g. caspase-8) as a consequence of death-receptor ligation can kill cells by stimulating the producing an effecter caspase such as caspase-3 (extrinsic pathway).
The "type II" cell types show optimal formation of death ligand-death ligand receptor complex, initiating a caspase cascade directly through activation of the mitochondrial pathway controlled by Bcl-2 family members (intrinsic pathway). Our results may be explained by the possibility that CYP26A1 expression affects both of these pathways. In addition, Bcl-2 is a member of an expanding family of related proteins. Some of these are antiapoptotic (Bcl-2, Bcl-X L ), some are pro-apoptotic (Bax, Bak). The importance of Bcl-2 family stemmed from observations that one mechanism for inducing apoptosis is associated with down-regulated expression of Bcl-2 or the altered equilibrium between these arbitrary two subsets to form homo-and hetero-dimers, which helps determine the susceptibility of the cells to death signal. One model is proposed that antiapoptotic Bcl-2 molecules are "guarding the mitochondria gate" from the pro-apoptotic Bcl-2 members that might otherwise "gain access" following a death signal (Gross et al., 1999) .
Highlighting the importance of Bcl-2 family in CYP26A1-mediated apoptotic inhibition, we found that CYP26A1 overexpression is clearly involved in the signaling cascades from death receptors, which converge on theBcl-2 family as a target relevant to epithelial cell survival.
Finally, our present study shows that many of the genes involved in apoptotic pathways are modulated to favor cell survival when CYP26A1 is overexpressed. It is possible that both during embryogenesis and in the adult, CYP26 enzymes may play a role in modulating cell sensitivity to RA and thus apoptogenic factor, which influence the sculpting process of tissue morphogenesis. This is supported by CYP26A1 knockout mouse experiments, which show animals lacking CYP26A1 suffering severe caudal agenesis and embryonic lethality (Abu-Abed This article has not been copyedited and formatted. The final version may differ from this version. We also show the densitometric analysis of the RARα signals on the blot from triplicate independent experiments. *, p<0.05 vs cell without RA treatment. Labeled cDNA was hybridized to apoptosis-pathway specific gene-expression array membranes. This article has not been copyedited and formatted. The final version may differ from this version. 
